QURE Stock Price
QURE
QURE stock price is $21.70 (+3.28% on the day), giving QURE a market cap of $1.47B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
QURE Stock Overview
- Price
- $21.70
- Previous close
- $21.01
- Open
- $21.25
- Market cap
- $1.47B
- 1-year price target
- $58.08
- MarketXLS Rank
- 43
About QURE
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | QURE | $21.70 | +3.3% | 1.17M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |